You are here: Home » News-CM » Companies » News
Business Standard

Alembic Pharmaceuticals receives USFDA approval for Solifenacin Succinate Tablets

Capital Market 

has received (USFDA) Approval for Succinate Tablets, 5 mg and 10 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Vesicare Tablets, 5 mg and 10 mg, of US, Inc. Succinate Tablet is a muscarinic antagonist indicated for the treatment of with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Succinate Tablets, 5 mg and 10 mg have an estimated market size of US$ 967 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 94 ANDA approvals (82 final approvals and 12 tentative approvals) from USFDA.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 21 2019. 10:23 IST